Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 9NET 7Gastrointestinal 2Thoracic 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Prostatic Neoplasms 731Carcinoma, Renal Cell 232Urinary Bladder Neoplasms 211Carcinoma, Transitional Cell 113Breast Neoplasms 100Kidney Neoplasms 95Neoplasms 88Carcinoma, Non-Small-Cell Lung 82Ovarian Neoplasms 80Melanoma 79Colorectal Neoplasms 73Neoplasm Metastasis 68Lung Neoplasms 58Non-Muscle Invasive Bladder Neoplasms 55Pancreatic Neoplasms 48Endometrial Neoplasms 45Sarcoma 43Stomach Neoplasms 40Uterine Cervical Neoplasms 39Carcinoma, Hepatocellular 34Adenocarcinoma 34Wilms Tumor 32Esophageal Neoplasms 31Triple Negative Breast Neoplasms 30Squamous Cell Carcinoma of Head and Neck 29Head and Neck Neoplasms 28Testicular Neoplasms 25Metastatic Castration-resistant Prostate Cancer 25Disease 24Colonic Neoplasms 24

Interventions

cabozantinib 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoid Tumor × Genitourinary × 90 days × Clear all
NCT05263050 2026-05-22

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Fox Chase Cancer Center

Phase 2 Recruiting
111 enrolled
EndocrineGenitourinaryNET

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡